Cardiovascular BioTherapeutics, Inc. Release: Leading Osteoporosis Researcher To Explore Potential Use Of Protein Therapy To Treat Osteoporosis

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT), a biopharmaceutical company focused on the development of protein-based drugs for the treatment of cardiovascular disease, today announced that it signed a sponsored research agreement with Tufts University School of Medicine to study the potential use of human fibroblast growth factor-1, the active component of Cardio Vascu-Grow™, to treat patients with osteoporosis.

Back to news